Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs ANTITUSSIVE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Antitussives suppress cough by acting on the cough center in the medulla oblongata (central antitussives) or by anesthetizing stretch receptors in the respiratory tract (peripheral antitussives).
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
FDA-approved: Symptomatic relief of nonproductive cough,Off-label: Cough associated with upper respiratory tract infections, chronic bronchitis, COPD
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
For dextromethorphan: 10-20 mg orally every 4-6 hours, maximum 120 mg/day. For codeine: 10-20 mg orally every 4-6 hours, maximum 120 mg/day.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Terminal elimination half-life is 3-6 hours in adults; prolonged in renal impairment (up to 12-18 hours).
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Metabolism varies by agent: Dextromethorphan is metabolized via CYP2D6; codeine (opioid antitussive) is metabolized via CYP2D6 to morphine; benzonatate is metabolized by plasma esterases.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Renal excretion of unchanged drug and metabolites (primarily glucuronide conjugates) accounts for approximately 60-80% of elimination, with biliary/fecal excretion contributing 15-25%.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
Approximately 35-45% bound to plasma albumin.
4-6 L/kg; large Vd indicates extensive tissue distribution
Vd approximately 3-5 L/kg, indicating extensive tissue distribution.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Oral: approximately 40-50% due to first-pass metabolism.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
GFR 30-50 m L/min: reduce dose by 25%; GFR 10-29 m L/min: reduce dose by 50%; GFR <10 m L/min: use with caution, avoid if possible.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Dextromethorphan: 2-6 years: 2.5-5 mg every 4-6 hours; 6-12 years: 5-10 mg every 4-6 hours; >12 years: adult dose. Codeine: not recommended for children due to safety concerns.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Initiate at lowest effective dose; monitor for sedation, constipation, and falls; avoid codeine if possible; dextromethorphan: 10 mg every 6-8 hours.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
N/A (No black box warning for general antitussives; specific agents like benzonatate have warnings for severe allergic reactions and accidental ingestion in children.)
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Do not exceed recommended dosage (risk of toxicity, especially with dextromethorphan abuse).,Caution in patients with respiratory depression, asthma, or chronic cough due to smoking or COPD.,Avoid in children <2 years (risk of serious adverse events).
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Hypersensitivity to the specific antitussive agent.,Concomitant use of MAOIs or within 14 days (risk of serotonin syndrome with dextromethorphan).,Respiratory depression (especially opioid-containing antitussives).
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Grapefruit juice may increase absorption of dextromethorphan, potentially increasing side effects. Avoid alcohol as it enhances CNS depression. No specific food restrictions for codeine, but avoid high-tyramine foods if taking MAOIs concurrently.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Antitussive agents (e.g., dextromethorphan, codeine) have limited data. Dextromethorphan: Animal studies show no teratogenicity; human data insufficient. Codeine: Risk of neonatal respiratory depression and withdrawal if used near term; possible association with congenital malformations in first trimester, but evidence inconclusive. Avoid use in first trimester and near term.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Dextromethorphan: Low levels in breast milk; M/P not established; generally compatible. Codeine: M/P ratio ~2.5; risk of CNS depression in infant; use caution or avoid. Monitor infant for sedation.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
No specific pharmacokinetic changes require dose adjustment for dextromethorphan. Codeine metabolism may be altered due to pregnancy-induced changes in CYP2D6; individual dose titration recommended, but avoid use if possible.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Antitussives like dextromethorphan are effective for nonproductive cough but should not be used in patients with chronic productive cough due to potential suppression of necessary mucus clearance. Abuse potential exists with dextromethorphan at high doses; monitor for serotonin syndrome when combined with MAOIs or SSRIs. Codeine-containing antitussives require caution in CYP2D6 ultra-rapid metabolizers due to risk of morphine toxicity.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
Take only for dry, hacking cough; do not use for cough with phlegm unless directed by a doctor.,Do not exceed recommended dose; excessive use can lead to serious side effects including confusion, hallucinations, and rapid heart rate.,Avoid alcohol and sedatives as they may increase drowsiness and respiratory depression.,Seek medical attention if cough persists >1 week, or is accompanied by fever, rash, or headache.,Do not combine with other cough/cold products containing the same active ingredients.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs ANTITUSSIVE, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. ANTITUSSIVE is a Antitussive that works by Antitussives suppress cough by acting on the cough center in the medulla oblongata (central antitussives) or by anesthetizing stretch receptors in the respiratory tract (peripheral antitussives).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and ANTITUSSIVE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of ANTITUSSIVE is: For dextromethorphan: 10-20 mg orally every 4-6 hours, maximum 120 mg/day. For codeine: 10-20 mg orally every 4-6 hours, maximum 120 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and ANTITUSSIVE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. ANTITUSSIVE is classified as Category C. Antitussive agents (e.g., dextromethorphan, codeine) have limited data. Dextromethorphan: Animal studies show no teratogenicity; human data insufficient. Codeine: Risk of neonatal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.